Literature DB >> 19593621

Gastrointestinal stromal tumor of the stomach with extremely slow-growing hematogenous metastasis.

Kentaro Kurashina1, Yoshinori Hosoya, Shinji Sakurai, Shunsuke Endo, Alan Lefor, Yoshikazu Yasuda.   

Abstract

A 67-year-old woman underwent resection of a gastric tumor and a synchronous metastatic lesion of the liver in 1991. Histopathologically, both the primary and metastatic tumors were diagnosed as leiomyosarcoma. Four years after the initial resection, another liver metastasis was detected in the caudate lobe, and a partial hepatectomy was performed. Multiple bilateral lung metastases were identified 7 years later and one was resected. Immunohistochemically, tissues from both the primary and metastatic sites were positive for KIT and CD34, and a c-kit gene mutation was found in the resected lung lesion. The remaining lung metastases responded to treatment with imatinib mesylate, but the treatment was discontinued because of toxicity. The patient remains under observation and the lung lesions have not progressed. At present she has no symptoms, and she has had no further recurrences in the past 3 years. This case is extremely unusual; a slowly progressing gastrointestinal stromal tumor over the course of 17 years from the initial diagnosis, with hematogenous metastases at multiple sites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593621     DOI: 10.1007/s10147-008-0834-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  14 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

Authors:  Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Hohenberger; Isabelle Ray-Coquard; Marcus Schlemmer; Allan T van Oosterom; David Goldstein; Raf Sciot; Pancras C W Hogendoorn; Michelle Brown; Rossella Bertulli; Ian R Judson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Left extended hepatectomy for a metastatic gastrointestinal stromal tumor after a disease-free interval of 17 years: report of a case.

Authors:  Lea Matsuoka; Maria Stapfer; Rod Mateo; Nicolas Jabbour; Win Naing; Rick Selby; Singh Gagandeep
Journal:  Surg Today       Date:  2007-01-01       Impact factor: 2.549

Review 4.  Gastrointestinal stromal tumor (GIST) and imatinib.

Authors:  Tetsuro Kubota
Journal:  Int J Clin Oncol       Date:  2006-06       Impact factor: 3.402

5.  Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Authors:  Chandrajit P Raut; Matthew Posner; Jayesh Desai; Jeffrey A Morgan; Suzanne George; David Zahrieh; Christopher D M Fletcher; George D Demetri; Monica M Bertagnolli
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

6.  [Resection for pulmonary metastasis of gastrointestinal stromal tumor of the stomach at 10 years after gastrectomy; report of a case].

Authors:  Y Inage; K Yamabe; T Yamamoto; Y Sato; S Ishikawa; M Onizuka; K Yoshida
Journal:  Kyobu Geka       Date:  2002-09

7.  Solitary fibrous tumor: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites.

Authors:  C A Hanau; M Miettinen
Journal:  Hum Pathol       Date:  1995-04       Impact factor: 3.466

8.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

Authors:  Samuel Singer; Brian P Rubin; Marcia L Lux; Chang-Jie Chen; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

9.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Authors:  Jean-Yves Blay; Axel Le Cesne; Isabelle Ray-Coquard; Binh Bui; Florence Duffaud; Catherine Delbaldo; Antoine Adenis; Patrice Viens; Maria Rios; Emmanuelle Bompas; Didier Cupissol; Cecile Guillemet; Pierre Kerbrat; Jérome Fayette; Sylvie Chabaud; Patrice Berthaud; David Perol
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

Review 10.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authors:  George D Demetri; Robert S Benjamin; Charles D Blanke; Jean-Yves Blay; Paolo Casali; Haesun Choi; Christopher L Corless; Maria Debiec-Rychter; Ronald P DeMatteo; David S Ettinger; George A Fisher; Christopher D M Fletcher; Alessandro Gronchi; Peter Hohenberger; Miranda Hughes; Heikki Joensuu; Ian Judson; Axel Le Cesne; Robert G Maki; Michael Morse; Alberto S Pappo; Peter W T Pisters; Chandrajit P Raut; Peter Reichardt; Douglas S Tyler; Annick D Van den Abbeele; Margaret von Mehren; Jeffrey D Wayne; John Zalcberg
Journal:  J Natl Compr Canc Netw       Date:  2007-07       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.